Joseph Rucker News Today

/PRNewswire/ -- Integral Molecular, a leading biotech company specializing in antibody discovery against undruggable protein targets will present multispecific...

PHILADELPHIA, Sept. 27, 2023 -- Context Therapeutics Inc. , a biopharmaceutical company advancing medicines for solid tumors, today announced a poster regarding the Company’s preclinical asset,...

Last summer, the American Historical Association’s former president, James H. Sweet, issued an apology. Expressing regret for “the way I have alienated some of my Black colleagues and friends,” Sweet walked back a claim he had earlier made that characterized as “anachronistic” and essentia...

CTIM-76 IND filing on track for Q1 2024 Preclinical data on CLDN6 bispecific antibody CTIM-76 presented at AACR Annual Meeting 2023 Cash and cash equivalents of $29.8 million as of March 31,... | May 10, 2023

CTIM-76 IND filing on track for Q1 2024 Preclinical data on CLDN6 bispecific antibody CTIM-76 presented at AACR Annual Meeting 2023 Cash and cash...

Context Therapeutics (NASDAQ:CNTX) Inc has designated CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target...

/PRNewswire/ -- Integral Molecular and Optimeos Life Sciences announce a partnership to develop next-generation mRNA and DNA therapeutics that will use...

Context Therapeutics (NASDAQ:CNTX) Inc, the womens cancer-focused group, has said its compounds are set to be showcased at the upcoming American...

Albert Labs (CSE:ABRT) International Corp, previously listed as ME Resource Corp, (MEC) shares have been approved for listing on the CSE. The psychedelic...

Albert Labs (CSE:ABRT) International Corp, previously listed as ME Resource Corp, (MEC) shares have been approved for listing on the CSE. The psychedelic...